Pelthos Therapeutics Inc.
Pelthos Therapeutics Inc.
Subscribe to unlock 17+ years of financial data
Subscribe to unlock 17+ years of data
Financial Statements
Values in Millions ($) | 2026-06-30 | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 | 2025-03-31 | 2024-12-31 | 2024-09-30 | 2024-06-30 | 2024-03-31 | 2023-12-31 | Subscriber-only column | Subscriber-only column | Subscriber-only column | Subscriber-only column | Financial statements beyond 3 years are for subscribers only. Unlock 17+ years of income statements, balance sheets, and cash flow statements Start 7-day free trial |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Cash | - | - | - | 14 | 0 | 0 | 1 | 1 | 2 | 4 | 0 | |||||
Assets | ||||||||||||||||
Assets Current | ||||||||||||||||
Nonrelated Party | - | - | 0 | - | - | - | 2 | - | - | - | - | |||||
Related Party | - | - | 0 | - | - | - | 2 | - | - | - | - | |||||
Cash And Cash Equivalents At Carrying Value | 24 | 32 | 18 | - | 0 | 0 | 1 | - | - | - | - | |||||
Deferred Offering Costs | - | - | 1 | - | 1 | 1 | 1 | 1 | - | - | - | |||||
Restricted Cash Current | 0 | 0 | 0 | 0 | 0 | 0 | 0 | - | - | - | - | |||||
Accounts And Other Receivables Net Current | - | - | - | 8 | - | - | - | - | - | - | - | |||||
Accounts Receivable Net Current | 14 | 12 | 9 | - | - | - | 0 | - | - | - | - | |||||
Inventory Net | 21 | 23 | 24 | 24 | - | - | 0 | - | - | - | - | |||||
Prepaid Expense And Other Assets Current | 3 | 2 | 3 | 3 | 0 | 0 | 0 | 0 | 0 | 0 | - | |||||
Cash And Due From Banks | - | - | - | - | 0 | 0 | 0 | 0 | 0 | 0 | - | |||||
Liabilities And Stockhold… | ||||||||||||||||
Assets Current | 63 | 70 | 53 | 50 | 1 | 1 | 1 | 2 | 3 | 4 | 0 | |||||
Liabilities Current | ||||||||||||||||
Accounts Payable And Accrued Liabilities Current | - | - | - | - | 5 | 3 | 2 | 1 | 1 | 2 | 5 | |||||
Property Plant And Equipment Net | 9 | 9 | 10 | 10 | - | - | 0 | - | - | - | - | |||||
Operating Lease Right Of Use Asset | 3 | 3 | 3 | 3 | - | - | 0 | - | - | - | - | |||||
Intangible Assets Net Excluding Goodwill | - | - | - | 33 | - | - | - | - | - | - | - | |||||
Finite Lived Intangible Assets Net | 37 | 38 | 39 | - | - | - | 0 | - | - | - | - | |||||
Goodwill | 25 | 25 | 25 | 31 | - | - | 0 | - | - | - | - | |||||
Assets | 137 | 145 | 130 | 126 | 1 | 1 | 1 | 2 | 3 | 4 | 0 | |||||
Accounts Payable Current | 6 | 6 | 3 | 6 | - | - | 2 | - | - | - | - | |||||
Accrued Liabilities Current | 21 | 13 | 15 | 12 | 0 | - | 0 | 0 | 0 | 0 | 1 | |||||
Bridge Loan | - | - | - | - | - | - | - | - | - | - | 0 | |||||
Other Loans Payable | - | - | - | - | 2 | 2 | 2 | 2 | 1 | - | 0 | |||||
Loans Payable | - | - | - | - | 0 | 0 | 0 | 0 | 0 | - | 1 | |||||
Asset Acquisition Contingent Consideration Liabili… | 1 | 1 | 2 | - | - | - | 0 | - | - | - | - | |||||
Operating Lease Liability Current | 1 | 1 | 1 | 1 | - | - | 0 | - | - | - | - | |||||
Deferred Revenue Current | - | - | - | 1 | - | - | - | - | - | - | - | |||||
Contract With Customer Liability Current | 1 | 1 | 1 | - | - | - | 0 | - | - | - | - | |||||
Other Liabilities Current | - | 3 | 4 | 6 | - | - | 0 | - | - | - | - | |||||
Liabilities Current | 32 | 25 | 26 | 25 | 7 | 5 | 4 | 4 | 3 | 3 | 7 | |||||
Operating Lease Liability | - | 3 | - | 3 | - | - | - | - | - | - | - | |||||
Deferred Revenue | - | - | - | 2 | - | - | - | - | - | - | - | |||||
Deferred Income Tax Liabilities Net | - | - | - | 13 | - | - | - | - | - | - | - | |||||
Operating Lease Liability Noncurrent | 3 | 3 | 3 | - | - | - | 0 | - | - | - | - | |||||
Contract With Customer Liability Noncurrent | 1 | 1 | 1 | - | - | - | 0 | - | - | - | - | |||||
Convertible Debt Noncurrent | 43 | 39 | 31 | - | - | - | 0 | - | - | - | - | |||||
Secured Long Term Debt | 27 | 26 | - | - | - | - | - | - | - | - | - | |||||
Other Liabilities Noncurrent | - | 32 | 30 | 26 | - | - | 0 | - | - | - | - | |||||
Liabilities | 139 | 126 | 92 | 68 | 7 | 5 | 4 | 4 | 3 | 3 | 7 | |||||
Stockholders Equity | ||||||||||||||||
Common Stock Value | 0 | 0 | 0 | - | 0 | 0 | 0 | 0 | 0 | 0 | 0 | |||||
Additional Paid In Capital | 110 | 107 | 104 | 101 | 20 | 19 | 19 | 18 | 18 | 17 | 7 | |||||
Accumulated Other Comprehensive Income Loss Net Of… | 2 | 2 | - | - | - | - | - | - | - | - | - | |||||
Retained Earnings Accumulated Deficit | -113 | -90 | -65 | -43 | -27 | -23 | -21 | -20 | -18 | -16 | -14 | |||||
Stockholders Equity | -2 | 19 | 39 | 58 | -6 | -4 | -3 | -1 | -0 | 1 | -6 | |||||
Liabilities And Stockholders Equity | 137 | 145 | 130 | 126 | 1 | 1 | 1 | 2 | 3 | 4 | 0 | |||||
Series A Preferred Stock | - | 0 | 0 | - | 0 | 0 | 0 | - | - | - | - | |||||
Series C Preferred Stock | - | 0 | 0 | - | - | 0 | 0 | - | - | - | - | |||||
Common Stock Par Or Stated Value Per Share | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | |||||
Common Stock Shares Authorized | 200 | 200 | 200 | 200 | 200 | 200 | 200 | 200 | 200 | 200 | 200 | |||||
Common Stock Shares Issued | 4 | 3 | 3 | 3 | 1 | 1 | 1 | 1 | 1 | 0 | 0 | |||||
Shares Outstanding | 4 | 3 | 3 | 3 | 1 | 1 | 1 | 1 | 1 | 1 | 0 | |||||
Subscribe to unlock 17+ years of financial data, unlimited metrics, and saved tables
Subscribe to unlock 17+ years of data, unlimited metrics, and saved tables
Custom Table
Subscribe to unlock 17+ years of financial data, unlimited metrics, transformations, and saved visuals
Subscribe to unlock 17+ years of data, unlimited metrics, transformations, and saved visuals
Interactive Financial Visualizations
Subscribe to unlock 17+ years of financial data
Subscribe to unlock 17+ years of data
Earnings Market Reaction
| Fiscal Year | Q1 1 Month | Q1 2 Month | Q1 3 Month | Q2 1 Month | Q2 2 Month | Q2 3 Month | Q3 1 Month | Q3 2 Month | Q3 3 Month | Q4 1 Month | Q4 2 Month | Q4 3 Month |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2026 | -7.73% | -6.93% | -5.20% | - | - | - | - | - | - | - | - | - |
| 2025 | 6.54% | 51.26% | 94.91% | 55.23% | 54.02% | 81.52% | -23.39% | -15.08% | -30.74% | -1.69% | 11.01% | 11.25% |
| 2024 | -32.70% | -41.71% | -52.13% | 17.52% | -16.73% | -16.08% | 30.27% | 24.80% | 265.05% | 24.32% | -32.43% | -17.09% |
| 2023 | - | - | - | - | - | - | - | - | - | 0.55% | -21.98% | -32.42% |
Earnings Market Reaction data beyond 3 years is for subscribers only. Unlock the full earnings market reaction history Start 7-day free trial | ||||||||||||
Subscribe to unlock 17+ years of financial data and 90+ calculated metrics
Subscribe to unlock 17+ years of data and 90+ calculated metrics
Performance and Valuation Metrics
Rows marked with a lock icon are subscribers only — subscribe to unlock 90+ calculated metrics and 17+ years of history.
Subscribe to unlock 17+ years of financial data
Subscribe to unlock 17+ years of data
Insider Transactions
Subscribe to unlock 17+ years of financial data
Subscribe to unlock 17+ years of data
Institutional Ownership
Pelthos Therapeutics Inc. (PTHS) — SEC Financial Statements & Analysis
Pelthos Therapeutics Inc. (PTHS) is a biological products, (no diagnostic substances) company, incorporated in NV. Pelthos Therapeutics Inc. trades on NYSE as: PTHS. Based on its latest SEC filing (Form 10-Q, period ending 2026-06-30), Pelthos Therapeutics Inc. reported a Gross Profit Margin of 78.59% (TTM), a Debt-to-Equity ratio of -92.51x, a Price-to-Sales (P/S) ratio of 2.31x (TTM), a Price-to-Book (P/B) ratio of -66.64x (TTM), at a market cap of $100.03M. Figures below are sourced from SEC EDGAR, as-filed.
- Gross Profit Margin TTM
- 78.59%
- Debt To Equity
- -92.51x
- P/S TTM
- 2.31x
- P/B TTM
- -66.64x
- Market Cap
- $100.03M
Data as of 2026-06-30 · Source: SEC EDGAR
Frequently Asked Questions
What industry is Pelthos Therapeutics Inc. in?
Pelthos Therapeutics Inc. (PTHS) operates in the Biological Products, (No Diagnostic Substances) industry.
What is PTHS's market cap?
Pelthos Therapeutics Inc. (PTHS) has a market capitalization of $100.03M as of 2026-06-30.
What exchange does PTHS trade on?
Pelthos Therapeutics Inc. (PTHS) trades on the NYSE.
Where is Pelthos Therapeutics Inc. incorporated?
Pelthos Therapeutics Inc. is incorporated in NV.